Merck & Co., Inc. (MRK)
| Market Cap | 215.81B |
| Revenue (ttm) | 63.62B |
| Net Income (ttm) | 16.41B |
| Shares Out | 2.50B |
| EPS (ttm) | 6.49 |
| PE Ratio | 13.32 |
| Forward PE | 9.44 |
| Dividend | $3.24 (3.75%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 9,695,658 |
| Open | 87.93 |
| Previous Close | 87.61 |
| Day's Range | 86.20 - 87.93 |
| 52-Week Range | 73.31 - 111.58 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 103.54 (+19.84%) |
| Earnings Date | Oct 30, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $103.54, which is an increase of 19.84% from the latest price.
News
Merck Completes Acquisition of Verona Pharma
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Completes Acquisition of Verona Pharma.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficac...
October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Oct. 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Merck: A Race Against The Keytruda Clock
Merck (MRK) is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a stron...
ABBV Stock vs. Eli Lilly & Merck
AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer's agreement to lower its drug prices for Medicaid and a White House decision...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Top 10 High-Yield Dividend Stocks For October 2025
The October 2025 high-yield dividend watchlist highlights 10 stocks with an average forward yield of 3.95% and a projected 19.02% return. This month's selection process lowered the yield threshold to ...
Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30.
S&P 500 Gains and Losses Today: Pfizer and Merck Jump; Payments Stocks Decline
An agreement with the U.S. government and a favorable regulatory decision in Europe helped lift shares of large drugmakers. Meanwhile, the announcement of a collaboration that will integrate shopping ...
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-pr...
Merck: Initiating "Strong Buy" On Shift To Qlex SC Injection For Solid Tumors
Merck earns a "Strong Buy" rating due to strategic moves, including FDA approval of QLEX, the first subcutaneous immune checkpoint inhibitor. QLEX extends Keytruda's patent life, offering rapid, flexi...
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept...
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Merck: Game-Changing Oncology Drugs Power Stock Surge
Despite the challenges Merck's vaccine franchise has faced, demand for its anti-cancer medications remains as high as ever. Welireg sales reached $162 million in Q2 2025, an increase of 18.2% quarter-...
Merck: 25% Total Return CAGR Potential
Merck & Co. is rated a Strong Buy at $79.89, offering robust growth, a 4% yield, and significant undervaluation. MRK's pipeline, led by Keytruda derivatives and new blockbusters from acquisitions like...
Merck's Keytruda gets an upgrade
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news.
Merck CEO Rob Davis on FDA approval of Keytruda injection, navigating new vaccine landscape
CNBC's Angelica Peebles and Merck chairman and CEO Rob Davis join 'Squawk Box' to discuss the FDA's approval of the injectable version of Keytruda, pricing for the new injection, navigating the new va...
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AIDD--Variational AI enters Collaboration with Merck to apply Generative AI Drug Discovery platform to design and optimize novel small molecule therapeu...
Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
Merck trades at 9.09x forward earnings, far below its 23.55x historical multiple and peers, while maintaining strong profitability and a 3.99% dividend yield. Blockbuster drug Keytruda, along with onc...